The FDA has awarded Fast Track designation to two drugs currently in development for CMT.
Daniel Levine from Global Genes speaks with Allison Moore on the Global Genes Rare Cast.
HNF to host an educational CMT symposium at AANEM’s Annual Conference October 10-13th in Washington, D.C.
True Reply and HNF have collaborated to enhance patient focused research and knowledge of what matters most to patients living with CMT.
StarWise Therapeutics LLC & HNF join forces to expedite the advancement of a new drug entity to the clinic for the treatment of CMT2A.
Learn how this CMT1A patient uses the AlterG treadmill to manage her CMT symptoms.
Invitae, A Genetic Information Company, Acquires AltaVoice, HNF’s Global Registry for Inherited Neuropathies (GRIN) Platform Host
New Collaboration with the University of North Carolina at Chapel Hill and The Jackson Laboratory Addresses Charcot-MarieTooth/Inherited Neuropathy Mutations Using Gene Therapy
HNF’s initial gene therapy work will focus on CMT type 6, which is caused by a recessive mutation in the C12orf65 gene and is currently no treatment.
A Bi-Directional, Translational Model of Resistance-Type Exercise Training in the Management of Charcot-Marie-Tooth (CMT) Disease
A team of government researchers, including Dr. Robert Chetlin, have collaborated with Dr. Michael Sereda and Dr. Klaus Nave of the Max Planck Institute for Experimental Medicine (MPI) to successfully secure the CMT1A transgenic rat from MPI and establish a colony in the United States.
Thanks to collaborative efforts of the University of Michigan Consortium for Stem Cell Therapies and molecular research scientists at Michigan-based Genesis Genetics, scientists are one step closer to understanding Charcot-Marie-Tooth disease.